Longeveron Inc. Stock News

The shares of Longeveron Inc. (NASDAQ: LGVN) increased by over 10% pre-market. This is why it happened.

Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced Friday results for a m

-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180

MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and

Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASD

Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based therapy) after promising res

MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related an

Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company's corporate outlook, Green participated in a panel entitled

- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer's Disease - Miami, Florida – June 24 th , 2021 - Longeveron Inc. (NASDAQ: LGVN)

- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer's Disease - Miami, Florida – June 24 th , 2021 - Longeveron Inc. (NASDAQ: LGVN)

Longeveron's (LGVN) CEO Geoff Green on Q1 2021 Results - Earnings Call Transcript

MIAMI, May 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l

Stem cell research is an arm of biotechnology that has gained a lot of momentum over recent years. Many companies are focused on developing therapies using specialized cells from within the human body

The stock price of Longeveron Inc. (Nasdaq: LGVN) increased by over 25% pre-market. This is why it happened.

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic agi